糖尿病预防新突破！司美格鲁肽为糖尿病前期人群带来双重福音

Core Viewpoint - The article emphasizes the critical role of managing prediabetes and obesity in preventing the progression to diabetes and cardiovascular diseases, highlighting the effectiveness of the drug Semaglutide (weight loss version) in improving health outcomes for overweight and prediabetic patients [5][6][20]. Group 1: Prediabetes and Health Risks - Prediabetes is a significant health warning signal, with 5%-10% of patients progressing to diabetes annually, and it is associated with increased cardiovascular risks [5][8]. - Meta-analysis shows that prediabetic patients have higher all-cause mortality and cardiovascular event rates compared to those with normal blood sugar levels [8][26]. Group 2: Obesity as a Risk Factor - There is a strong positive correlation between obesity and the risk of prediabetes, with risk increasing significantly as BMI rises: 25% increase for BMI 25.0-29.9 kg/m² and 184% for BMI ≥40 kg/m² [9][11]. - The 2023 Expert Consensus on Diabetes Prediabetes Intervention emphasizes weight management as a core strategy to prevent the progression of prediabetes [9][11]. Group 3: Semaglutide's Impact - The SELECT study demonstrated that Semaglutide (weight loss version) significantly reduces the risk of major cardiovascular adverse events (MACE) by 20% compared to placebo [17][18]. - The drug also shows remarkable effects on blood sugar control, with nearly 70% of patients achieving normal blood sugar levels, far exceeding the placebo group [18][20]. Group 4: Future Outlook - There is optimism that more prediabetic patients will receive early intervention, leading to improved long-term outcomes for overweight and obese individuals [21][22]. - The treatment of metabolic diseases is expected to enter a new era of precision and individualization [22].